Skip to main content
REPLIGEN CORP logo

REPLIGEN CORP — Investor Relations & Filings

Ticker · RGEN ISIN · US7599161095 LEI · 54930006QJ0T5AUO1E71 US Manufacturing
Open in API
Filings indexed 1,029 across all filing types
Latest filing 2026-05-15 Declaration of Voting R…
Country US United States of America
Listing US RGEN

About REPLIGEN CORP

https://www.repligen.com/

Repligen Corporation is a life sciences company that develops and commercializes innovative bioprocessing technologies and systems used in the manufacturing of biologic drugs. The company's portfolio is focused on enhancing efficiency and quality in biopharmaceutical production workflows. Key product areas include filtration, featuring Tangential Flow Filtration (TFF) systems; fluid management, with single-use technologies such as bags, assemblies, and mixers; and process analytics, offering advanced instruments for concentration measurement. Repligen's technologies are integral to the development and cGMP manufacturing of therapies like monoclonal antibodies, vaccines, and cell and gene therapies.

Recent filings

Filing Released Lang Actions
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is a U.S. SEC Form 8-K “Current Report” filed May 14, 2026, containing Item 5.07 “Submission of Matters to a Vote of Security Holders,” with detailed voting results for proposals at the 2026 Annual Meeting (election of directors, ratification of auditors, advisory vote). This matches the definition of “Declaration of Voting Results & Voting Rights Announcements” (DVA).
2026-05-15 English
10-Q - REPLIGEN CORP (0000730272) (Filer)
Interim / Quarterly Report
2026-05-06 English
8-K - REPLIGEN CORP (0000730272) (Filer)
Earnings Release Classification · 93% confidence The document is a U.S. SEC Form 8-K reporting Item 2.02 "Results of Operations and Financial Condition" and attaches a press release announcing first quarter financial results. This aligns with an initial earnings announcement rather than a full interim report. Therefore it should be classified as an Earnings Release (ER). Q1 2026
2026-05-05 English
DEFA14A
Proxy Solicitation & Information Statement
2026-04-27 English
ARS
Annual Report
2026-04-02 English
DEFA14A
Proxy Solicitation & Information Statement
2026-04-02 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.